From his beginnings as a carpet salesman while attending the University of Michigan, Erick Lefkofsky has built his personal and professional brand from the ground up. Since leaving law school in 1993, his entrepreneurial spirit has led him and college friend Brad Keywell to achieve funding to invest in an apparel company called Brandon Apparel. He went on to realize a product promoting company in the early days of internet business called Starbelly in 1999. After selling Starbelly to Halo Industries, Lefkofsky went on to become a chief operating officer for Halo. Lefkofsky also co-founded InnerWorkings, created Echo Global Logistics, and along with Keywell, co-founded the company MediaBank, just to name a few of his earliest accomplishments.
Lefkofsky makes it a point to give back to his community through numerous philanthropic endeavors. Along with his wife, Lefkofsky established the Lefkofsky Foundation, a charitable trust that serves the sole purpose of providing charitable scientific and educational support for certain humanitarian causes and organizations across the world. It has helped fund more than fifty organizations so far and has a high concentration on helping children related causes.Apart from the Lefkofsky Foundation, Erick Lefkofsky is a member of the Children’s Memorial Hospital in Chicago and currently serves as one of its board of directors. He is also currently on the board of board directors for The Museum of Science and Industry, The Art Institute of Chicago, and is involved with Steppenwolf Theatre Company as a trustee. Along with giving back to his community with these numerous positions, he has also served as a supporter for the 2016 Summer Olympics in Chicago by joining the committee at the time to bring the event to Chicago.
Erick Lefkofsky not only has an appreciation and support for higher education, he has also provided education to numerous students by lending his industry knowledge at Chicago area schools of business. He continues his practices today at the University of Chicago Booth School of Business as an Adjunct Professor where his knowledge of entrepreneurship is imparted on his students, as well as his in depth knowledge in building businesses geared towards technology.
3The Cancer Treatment Centers of America is creating a huge amount of change in the medical field with how they are trying to revolutionize different ideas, programs, and solutions to help physicians and patients. They teamed up with two excellent companies to build a brand new type of technology that is going to make it easy for patients to know what their body needs. Clinical Pathways is a new program that will provide patients with an up to date list of treatments customized to their current state of health. As we all know, a treatment before a certain type of therapy before a certain time may not be the right choice down the road. It’s important to be careful and to make sure to get what the physicians know what is best.
As stated on Wikipedia, with the help of Clinical Pathways, physicians have a lot of their work cut out for them because of the fact that this program does all of the hard work while the doctor does what they’re able to do. Customization is the key is to provide the patients with what they need and what kind of guidance they can receive. This new program is beyond important to think about because of the fact that patients can receive all the help they need to grow and be able to know what suits their health at the current state.
The Cancer Treatment Centers of America loves to respect and guide their patients. They do what they can to help with giving their patients all the help to get them back on the road to recovery. They love what they do and what they offer, and they can give their patients even more help with the power of Clinical Pathways. Their service has remained noble, and countless people praise them for the work they do. CTCA blog: https://www.myctca.com/
Dr. Clay Siegall, Ph.D., is the President, CEO and Board Chairman of Seattle Genetics. According to Seattlegenetics.com, Siegall established the firm in 1998 on a strong scientific, research and drug development platform. Siegall has been instrumental in overseeing several groundbreaking studies, including the development of ADCs or antibody drug conjugates. One of the most successful, internationally acclaimed ADC products from the company is ADCETRIS (brentumixmab vedotin), which has been prescribed to fight lymphomas. The brand is now available in over 60 countries around the world. Under the guidance of Dr. Siegall, the firm has also signed several strategic licenses with world leading drug makers such as Pfizer, GlaxoSmithKline and Roche.
The strategic partnerships signed by Seattle Genetics for its flagship ADC drugs have generated over $320 million. Dr. Siegall has also been instrumental in spearheaded various fundraising ventures to raise capital for various research initiatives. The company has so far raised over $2 billion from its 2001 IPO and contributions from private and public donors. Prior to establishing Seattle Genetics, Dr. Clay Siegall worked at various internationally recognized research organizations. According to an overview published by Crunchbase, Dr. Siegall served at the National Cancer Institute (NCI), National Institutes of Health for duration of 3 years from 1988 to 1991. He later moved to Bristol-Myers Squibb Pharmaceuticals Research Institute to work as lead researcher from 1991 to 1997.
A quick look at various publications, blogs and online reviews reveals many positive things about Dr. Siegall and his company. According to the Human Daddy blog, Glass Door paints Seattle Genetics as having a great campus and a productive, small company feel. Dr. Siegall and Seattle Genetics have also received admirable reviews from the Forbes and Hackronym.com blogs. Dr Siegall got involved in the front lines of fighting cancer research after his late father was diagnosed with brain cancer. He studied for his Bachelor’s of Science degree in Zoology at the University of Maryland, before advancing for his PhD in Genetics at George Washington University. To cap his roll of achievements, Dr. Siegall holds 15 patents and over 70 publications to his credit.